Equities Analysts Issue Forecasts for Biotricity Q3 Earnings

Biotricity, Inc. (NASDAQ:BTCY) – Equities research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Biotricity in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst K. Dede expects that the company will post earnings of ($0.11) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Biotricity’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Biotricity’s Q4 2025 earnings at ($0.11) EPS.

Biotricity Stock Performance

Shares of BTCY stock opened at $0.31 on Tuesday. The firm has a market capitalization of $7.12 million, a price-to-earnings ratio of -0.27 and a beta of 1.22. The company has a 50 day moving average price of $0.34 and a 200 day moving average price of $0.64. Biotricity has a one year low of $0.19 and a one year high of $1.67.

Biotricity (NASDAQ:BTCY) last released its earnings results on Monday, August 19th. The company reported ($0.49) EPS for the quarter. The company had revenue of $3.20 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biotricity stock. AE Wealth Management LLC purchased a new position in Biotricity, Inc. (NASDAQ:BTCY) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 97,751 shares of the company’s stock, valued at approximately $88,000. AE Wealth Management LLC owned about 0.45% of Biotricity at the end of the most recent quarter. 3.89% of the stock is owned by institutional investors and hedge funds.

Biotricity Company Profile

Biotricity, Inc, a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.